Profusa Inc (PFSA)

$PFSA: 2nd RS this year already........................

Now at $2.30


Are they gonna go for a 3rd or 4th RS this year ?

We're only 1/2way thru and these are the kinda antics they got.

So whats it gonna be ???

Produce some POSITIVE news maybe ??????????????

Whatta joke.............. was $250 in January and now $2.50 with all the RS'es factored in.


GO $PFSA

$PFSA Half The float of $SDOT

$PFSA Same Float as $NVVE similar setup as $CLRO Gave you guys that one in the 2$s ran to 16$ i sold way to early as usual

$PFSA
same float as
$NVVE
at a quarter of the price, see if they come for it soon

Sold all shares of PFSA and put the proceeds into ADTX. Believing it will be a better long term play.

WHO is PanOmics that PFSA plans to buy? https://www.panomics.bio/

Paid $1.83 a share for this back in April and sold it for $.587. Had a bunch of shares. Was so painful.

So now I'm seeking vengeance. Bought 3,000,0000 shares this time under $.12. We'll see how the path winds ...

Loaded up at $.1190 earlier.

ADTX seems to be the stock of the week. I build mine up to 435K but sold some to buy PFSA.

PFSA...........................................p/m

Looks like we might have a winner here.

$2+ 😃

$PFSA 💹

PFSA.............................................https://stockcharts.com/sc3/ui/?s=PFSA&p=w&b=5&g=0&id=p86431144783

$1.70+ 😃

$PFSA 💹

PFSA............................................................p/m

Hopefully it runs this week, then going to add on three OTC's this week, added another 8000 shares of $TGLO to my stash.

Got some…let’s see.
Thanks for sharing.
PFSA

Getting ready to pop. This week with news easy double or triple from here.

By when?  
Milestone I and Milestone II have price targets of $12.50 and $14.50 for 20 out of 30 days, and both expire on 7/11/2027.
Neither of these are possible without the Tasly Joint Venture.
Heck, even Milestone IV is unachievable (earnings of $11.84 million in 2026) without the TJV.
Nor is NASDAQ compliance ($50 million Market Cap) by 3/10/26 possible w/o the TJV.
The NASDAQ requirement for PFSA to be at or above $1 by 3/10/26 is certainly doable via a reverse split, but why bother if the market cap requirement isn't met?
Short term and bottom line.....ProfUSA needs to complete the TJV and sweeten the terms substantially, and do it really soon....

PT 5$

Getting interesting..................................

Countdown to 3/10/26.

WHAT could management possibly be working on to keep their 2026 momentum moving in the right direction?

STUDY the financials.

Loving this action today (Tuesday, 1/6/2026).

PFSA has been slowly and fairly steadily rising all day, on elevated volume (1:00 pm, +17%, volume = 17.25 million vs daily average of 25.06 m).

I'd like to think this is market maker accumulation in anticipation of a major and market moving Press Release within the next 24 to 30 hrs.

If anything significant happened on the last day of 2025, ProfUSA has an obligation to release this to the public by end of day tomorrow.

I'd really love to see a nice uptick in volume and price during the last 15 to 30 minutes of today's power hour.

Godspeed to all who have accumulated during this dip below 10 cents.

MS III

Do the math.  A P/E ratio of 10 isn't unreasonable.  Then you just need to know what the number of shares will be.  
EARNINGS X P/E = Price (of all the shares), which is Market Cap
Then divide that number by what you believe the number of shares might be in 2030

I’ve been following NorthView / ProfUSA since NVAC’s formation and wanted to lay out a brief timeline tied to Milestone III and ask an open question.

Key points (all from public filings):

ProfUSA founded in 2009

Tasly has had an investment/collaboration relationship with ProfUSA since at least 2018

APAC JV discussions date back to ~2020

ProfUSA Asia Pacific Pte. Ltd. was formed in Singapore in August 2023

Binding Tasly term agreement disclosed July 30, 2024

NVAC–ProfUSA merger closed July 11, 2025

Per the merger agreement, founders are eligible for 3,875,000 earnout shares, split evenly across four milestones. Milestone III requires completion of the Tasly JV by 12/31/25, including Tasly purchasing 60% of the JV for $6M.

Other observations:

Over $2M of the JV consideration has already been funded

Projected revenues disclosed in late-2025 filings appear insufficient to support later milestones without the JV

Failure to complete Milestone III would eliminate eligibility for all remaining earnout shares

The recent debt restructuring involved unusually favorable concessions

A reverse split alone does not address Nasdaq market-cap or public-float requirements

Question:
Given the material importance of Milestone III, does it seem reasonable to expect a definitive disclosure—positive or negative—by the required SEC reporting deadline? If not, what am I missing?

I welcome counterpoints, corrections, or additional publicly available information.

This post is intended solely to encourage discussion and the sharing of publicly available information.

My posts are merely my unprofessional opinion and should NEVER be seen as or used as investment advice.

PFSA news .. Profusa Bolsters European Commercial Network with New French Distributor, MedSell
https://finance.yahoo.com/news/profusa-bolsters-european-commercial-network-123000421.html

"I-am-the-way-the-truth-and-the-life....As-well-the-creator-of-those-blue-skies".....How-about-setting-your-blue eyes on Him (listening to and studying His holy word). And let's do so daily......And if you want to do the annual fasting thing do that as well but do it with a right heart and not a cranky one......Just my advise......

Hey Buddy, are you and Blu Skys still watching Northview (Now ProfUSA)?

I've been studying this in depth for years, and with the help of ChatGPT (AI), I am keeping my eyes open for a huge announcement to start off 2026, that has its roots in Singapore no less.

Has anyone else been looking into this?

Best of luck to all in 2026! Happy New Year!

$PFSA : Rolling this am.................. now $0.15

Let see if it can get $0.30


GO $PFSA

PFSA..........................................out

What will PPS be in 2030, if all that Revenue predicted happens? Anyone have a guess?

pfsa................................................................https://stockcharts.com/sc3/ui/?s=pfsa&p=W&b=5&g=0&id=p86431144783

$0.40+ 😃

$PFSA 💹

Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026

Oct 28, 2025

Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces completion of key manufacturing initiatives to support 2026 Lumee™ tissue oxygen monitoring revenue targets.

“Our team is laser-focused on achieving revenue from sales of Lumee™ tissue oxygen monitoring systems to our customers in the beginning of the second quarter of 2026. Our manufacturing and supply chain projects are on track to provide inventory to our distributors in the first quarter of 2026 to support 2026 revenue projections,” said Fred Knechtel, Profusa’s CFO.

“We are driven by the positive momentum received from our distributors and growing network of clinical and research customers and look forward to serving the unmet clinical need for tissue oxygen monitoring with our innovative Lumee technology platform,” added Ben Hwang, Ph.D., Profusa’s Chairman and CEO.

Manufacturing milestones achieved to-date include:

Completed first sensor production run in its recently constructed CER (Controlled Environment Room) in October. Production capacity is more than 2x the sensors required to achieve 2026 revenue targets

Engaged contract manufacturer to produce Lumee patch/readers and pens.
• Pen production began in October and capacity is more than 2x the pens required to achieve 2026 revenue targets

• Lumee patch/reader manufacturing first production run is expected in November. Production capacity is more than 2x the patch/readers required to achieve 2026 revenue targets

As previously announced, Profusa intends to partner with distributors AngioPro and Dismeval, S.L, which covers ~35% of European procedures, and confirmed initial 3 key opinion leader commercial and clinical collaborations. Profusa estimates the 2025 European CLTI (Critical Limb Threating Ischemia) market is comprised of more than 700,000 procedures.

About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924

https://investorshub.advfn.com/stock-market/NASDAQ/profusa-PFSA/stock-news/97092512/profusa-completes-manufacturing-build-out-on-trac

$PFSA

Profusa Unveils Strategic Focus in Investor Update

Oct 21, 2025

On October 20, 2025, Profusa, Inc. released an updated investor presentation, highlighting its strategic focus on expanding its commercial stage Oxygen Platform and launching the Lumee tissue oxygen monitoring product in Europe and the US by 2027. The company projects significant revenue growth, from $0.5-2 million in 2026 to $200-250 million by 2030, driven by its innovative AI-driven healthcare technologies and robust data discovery platform. Profusa’s operational focus includes collaborations in key EU markets, a distribution network covering 35% of the EU market, and partnerships with high-volume centers to enhance its market positioning.

More about Profusa
Profusa, Inc. operates in the healthcare technology industry, focusing on pioneering real-time biochemistry solutions that drive AI-led personalized healthcare technologies. The company is involved in developing platform technologies that offer multiple commercial revenue opportunities, particularly in tissue and pulse oximetry oxygen monitoring, with a significant market presence in the US and Europe.

https://www.msn.com/en-us/money/other/profusa-unveils-strategic-focus-in-investor-update/ar-AA1OT83h

$PFSA

Charting up,bought 15k .3699

Only volume surge so far has been a red wave lol

Bought some .4068 and under,bids in if it dips. Only a few hundred in this so far,very risky lotto

Could be a play again soon,hit zero borrow this morning,(I can still see 250k to short but with volume those could disappear quickly) I am watching closely for demand and volume as death hour ends at 11:30(watch for start 11:15ish) if no demand or volume I won’t be buying

For me, it's just a trade/flip, but yes.

Rotten financials, be careful

Yup

Selling a bunch I bought yesterday

PFSA news .. Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
https://investorshub.advfn.com/stock-market/NASDAQ/profusa-PFSA/stock-news/96802230/profusa-adopts-nvidia-powered-technology-to-build

pfsa.............................................................p/m

Insiders now a bit over 37%.

And let's see them make lot's of money!!!!!!

Insiders have bought themselves this month from about 15% to 34% position.

Let's see if they continue it.

Apparently, question is, do they have one last one in them?

loaded the bottom here. Potentially still a nice gainer. Keeping it on watch. 

PFSA , Pump and dump , Again?